Strategy & Innovation Diagnostics for Startup Success
Helping HealthTech, MedTech and Wellbeing startups diagnose issues and opportunities across business strategy, innovation strategy, product strategy and product innovation to build stronger businesses and increase the probability of product success.
Why Promising Products Struggle
Many products struggle not because of a lack of effort, innovation or ambition, but because important strategic decisions were made before enough clarity existed around the product, market, organisation and conditions required for success.
What begins as momentum can gradually create uncertainty.
Questions around customer needs, product value, feasibility, adoption or commercial viability can remain unresolved while development effort, investment and expectations continue increasing.
In HealthTech, MedTech and Wellbeing environments, these challenges rarely stay isolated.
Products influence adoption.
Adoption influences growth.
Regulatory and operational realities influence what is feasible, scalable and sustainable.
Small assumptions made early can gradually become larger and more expensive problems later.
Many products struggle not because of a lack of effort, innovation or ambition, but because important decisions were made before enough clarity existed around the product, the user and the conditions required for success.
How We Help
Building confidence in the decisions that matter most.
IGNITE Diagnostics helps founders and leadership teams build confidence that they are developing the right product, for the right users and in the right way before larger commitments are made.
The diagnostics are designed to identify where uncertainty, weak assumptions or hidden risks may be affecting:
→ product direction
→ feasibility and viability
→ customer adoption
→ early growth decisions
before these issues become harder, riskier and more expensive to address later.
The work connects product, market and organisational factors to understand what most strongly influences whether products:
→ gain traction
→ achieve product-market fit
→ scale successfully, or
→ struggle to create sustainable value
The outcome is greater clarity about what is really happening, why it is happening and where strategic attention should be focused first. That understanding helps organisations address existing challenges more effectively and reduce the likelihood of creating larger ones later.
Rather than overwhelming teams with process or consulting theatre, the emphasis remains practical, commercially grounded and focused on helping ventures make better decisions with greater confidence.
Services
Diagnostics for Creating Successful Products
Clarifying the problem, user needs, product direction and development priorities before major commitments are made.
Explore services:
Diagnostics for Building Successful Startups
Strengthening feasibility, regulatory readiness, commercial foundations and responsible product development early.
Explore services:
Diagnostics for Wining Customers
Improving go-to-market readiness, customer alignment and adoption potential before scaling activity accelerates.
Explore services:
Together, these diagnostics help founders and leadership teams create stronger foundations for product, market, organisational and growth decisions before uncertainty becomes embedded into development, operational or commercial activity.
IGNITE Diagnostics forms part of JASSELL Advisory’s wider Strategy & Innovation Consulting practice for HealthTech, MedTech and Wellbeing product-led businesses, connecting product, market and organisational factors to increase the probability of product success.
Product Direction Diagnosis
Avoid waste. Move with confidence.
Issues
Early-stage teams often move quickly before they fully understand the problem, the user or the value the product must create. Ideas evolve, assumptions multiply and decisions begin to feel increasingly uncertain as pressure to progress builds.
Aim
This diagnostic helps founders and leadership teams assess whether product direction remains clear, grounded and aligned with real user needs before development, investment or design decisions begin accelerating in the wrong direction.
Why it matters
Early-stage products can struggle for many reasons. One of the most common is a lack of clarity around the problem being solved, the user being served or the value the product must ultimately create.
As uncertainty increases, assumptions begin replacing evidence. Features become harder to prioritise, decision-making loses focus and development effort can drift away from what customers genuinely need or value.
Without early clarity, organisations risk investing time, money and development effort into products that solve the wrong problem — or solve the right problem in the wrong way.
The risks
Research from Harvard Business Review (2013), the Journal of Service Research (2007) and Forrester Research (2021) shows that weak customer understanding, behavioural mismatch and poor early insight practices are strong predictors of weak adoption, reduced engagement and early product failure.
These risks rarely emerge through one major decision. More often, they build gradually through unclear assumptions, fragmented user understanding and product decisions that drift further away from real customer behaviour and needs.
How we help
The diagnostic examines problem definition, user understanding, value proposition and early product assumptions to identify where uncertainty, weak alignment or assumption-driven thinking may be creating risk.
The work helps founders and leadership teams understand whether the product direction remains grounded in genuine user need, where assumptions require validation and what requires attention before development or investment decisions move further forward
What you recieve
• review of product direction, assumptions and value logic
• assessment of user understanding and problem clarity
• identification of behavioural gaps and uncertainty risks
• evaluation of early product and decision alignment
• product direction and validation recommendations
:
What improves
Organisations leave with clearer visibility of product direction risks, stronger understanding of user and value alignment and better-informed decisions around validation, prioritisation and early product development.
The result is a more focused and evidence-based product direction — with reduced uncertainty, stronger decision-making and greater confidence before major commitments are made
Product-Market Fit Diagnosis
Know your customers. Build what they’ll buy.
Issues
Many early-stage products struggle not because the idea is weak, but because they fail to fit how people behave, decide and adopt solutions in real life. Teams often build products that make sense internally but do not align naturally with real customer behaviour, expectations or trust patterns.
Aim
This diagnostic helps founders and leadership teams assess whether the product genuinely fits customer needs, behaviours and adoption drivers – before development, positioning or go-to-market decisions become harder and more expensive to change later.
Why it matters
Products rarely fail because the technology does not work. More often, they fail because customer behaviour, trust and real-world adoption barriers were not understood clearly enough early on.
As assumptions replace insight, teams can begin building features, experiences and messaging that feel logical internally but fail to connect with how people actually think, behave or make decisions in practice. Over time, this weakens adoption, slows traction and increases the risk of building something customers simply do not value enough to use consistently or buy confidently
The risks
Research from Harvard Business Review (2013), the Journal of Service Research (2007) and Forrester Research (2021) shows that behavioural mismatch, unclear value communication and weak customer insight practices are strong predictors of poor adoption, early churn and weak product-market fit.
These risks rarely emerge through one major failure. More often, they build gradually through friction, weak trust signals, assumption-driven decisions and products that fail to align naturally with how customers behave and adopt solutions in real-world environments
How we help
The diagnostic examines customer behaviour, adoption drivers, perceived value, trust factors and usage patterns to identify where friction, weak alignment or behavioural gaps may be limiting adoption and engagement.
The work helps founders and leadership teams understand how customers experience the product today, where adoption barriers may exist and what requires attention before larger decisions around design, positioning or go-to-market activity move forward.
What you recieve
• review of customer behaviour and adoption patterns
• assessment of value perception, trust and engagement drivers
• identification of friction points and behavioural gaps
• evaluation of product-market fit assumptions and alignment
• adoption and product-market fit recommendations
What improves
Organisations leave with clearer visibility of adoption risks, stronger understanding of customer behaviour and better-informed decisions around product design, positioning and go-to-market priorities.
The result is a more behaviourally aligned and commercially credible product experience — with stronger adoption potential, reduced friction and greater confidence in achieving early product-market fit.
Product Development Diagnosis
Set the direction. Shape the journey.
Issues
Early-stage teams often reach a point where they understand the problem, the user and the opportunity – but lack a clear plan for what to build first and why. Energy is high, but structure is missing. Priorities compete, feature ideas expand and roadmaps become increasingly difficult to sequence confidently.
Aim
This diagnostic helps founders and leadership teams assess whether product strategy, development priorities and early planning remain focused, achievable and aligned with real user, operational and commercial needs – before development effort accelerates in the wrong direction.
Why it matters
Many teams begin building too quickly, adding features and development activity based on assumptions rather than evidence. As complexity grows, priorities become less clear, MVPs expand beyond what is realistic and product decisions drift further away from what users genuinely value or what the organisation can feasibly support early on.
Without a disciplined strategy and development plan, teams risk building too much, too soon — increasing waste, slowing progress and making future changes significantly harder and more expensive to manage.
The risks
Research from MIT Sloan Management Review (2020) and the International Journal of Managerial Studies and Research (2020) shows that organisations often experience strategic drift when priorities, assumptions and development decisions become misaligned with evolving customer, operational and market realities.
These risks rarely emerge through one major planning mistake. More often, they build gradually through over-scoped roadmaps, weak prioritisation, assumption-driven decisions and development plans that become increasingly disconnected from real user behaviour, feasibility or strategic focus.
How we help
The diagnostic examines product direction, value drivers, MVP definition, feature prioritisation and development sequencing to identify where complexity, weak alignment or assumption-driven planning may be creating risk.
The work helps founders and leadership teams understand what should be built first, where priorities require clearer focus and what requires attention before larger development commitments, roadmap expansion or resource investment move further forward.
What you recieve
• review of product strategy, roadmap and development priorities
• assessment of MVP scope, sequencing and feasibility alignment
• identification of complexity, prioritisation and planning risks
• evaluation of user, operational and commercial alignment
• product strategy and development planning recommendations
What improves
Organisations leave with clearer visibility of strategy and planning risks, stronger understanding of development priorities and better-informed decisions around sequencing, scope and early product investment.
The result is a more focused and achievable development pathway — with clearer priorities, reduced complexity and greater confidence in the decisions shaping early product progress.
Regulatory & Sustainability Diagnosis
Move confidently. Build responsibly.
Issues
In HealthTech, MedTech and other regulated product environments, early decisions shape everything that follows — including feasibility, safety, compliance, operational viability and long-term trust. Yet many early-stage teams move quickly before they fully understand the regulatory, risk or sustainability requirements surrounding the product.
As development progresses, uncertainty can begin accumulating beneath the surface. Validation pathways become less clear, assumptions remain untested and important risks may only emerge after significant time, cost and effort have already been invested.
Aim
This diagnostic helps founders and leadership teams assess whether the product remains feasible, responsible and aligned with regulatory and sustainability expectations before larger commitments become harder and more expensive to change.
Why it matters?
Many promising products struggle not because demand is weak, but because feasibility, compliance or operational realities were not considered clearly enough early on. Teams often focus heavily on innovation and speed while underestimating the complexity of regulatory expectations, validation requirements or sustainability pressures that emerge later.
As uncertainty builds, organisations risk making early product or operational decisions that create downstream constraints, increase development costs or weaken long-term credibility and trust.
Without early clarity, teams may invest heavily in products that are desirable in theory but difficult to validate, scale responsibly or bring to market successfully.
The risks
Research from the Journal of Operations Management (2004), OECD (2020) and the U.S. Food and Drug Administration (2021) shows that organisations often experience increased operational, regulatory and commercial risk when product decisions, quality systems and compliance considerations fail to evolve together early in development.
These risks rarely emerge through one major mistake. More often, they build gradually through weak process discipline, unclear regulatory pathways, missing validation evidence and early decisions that become increasingly difficult and expensive to reverse later.
How we help
The diagnostic examines regulatory readiness, product feasibility, validation expectations, sustainability considerations and early operational alignment to identify where uncertainty, exposure or weak assumptions may be creating risk.
The work helps founders and leadership teams understand what requirements may affect development, where hidden constraints or gaps exist and what requires attention before product, investment or external engagement decisions move further forward.
What you recieve
• review of early feasibility, regulatory and sustainability considerations
• assessment of validation expectations and compliance readiness
• identification of operational, regulatory and development risks
• evaluation of early product and process alignment
• feasibility, regulatory and responsible development recommendations
What improves
Organisations leave with clearer visibility of feasibility and compliance risks, stronger understanding of regulatory and sustainability expectations and better-informed decisions around development, validation and investment priorities.
The result is a more credible and defensible development pathway — with reduced uncertainty, fewer downstream surprises and greater confidence in the decisions shaping early product progress.
Business Model Diagnosis
See the value. See the viability.
Issues
Many early-stage products are built around a strong idea or compelling technology but without a clear and workable business model behind them. Teams focus heavily on the product itself while leaving pricing, value capture and commercial assumptions vague, incomplete or untested.
As development progresses, uncertainty around commercial viability often increases. Customer segments become less clear, pricing logic weakens and important assumptions about how value will be created, delivered or monetised remain unresolved.
Aim
This diagnostic helps founders and leadership teams assess whether the commercial foundations behind the product remain realistic, aligned and capable of supporting sustainable growth before larger investment or scaling decisions move forward.
Why it matters
Products rarely fail because they do not work. More often, they fail because the business model behind them lacks clarity, alignment or commercial realism. Teams may build something technically impressive or highly desirable but struggle to translate that value into sustainable revenue, customer commitment or long-term commercial viability.
As assumptions replace evidence, pricing decisions become uncertain, offerings drift away from customer priorities and commercial exposure increases. Over time, this weakens confidence, slows traction and creates increasing pressure around investment, growth and sustainability.
Without early commercial clarity, organisations risk building products that customers may like – but are unwilling or unable to pay for consistently.
The risks
Research from the Strategic Management Journal (2007), Harvard Business School (2016) and OECD (2021) shows that organisations often experience strategic and commercial drift when value creation, customer behaviour and revenue logic fail to evolve together as markets, technologies and expectations change.
These risks rarely emerge through one major commercial failure. More often, they build gradually through unclear pricing logic, weak value capture, misaligned customer assumptions and business models that become increasingly disconnected from how customers actually make decisions and perceive value.
How we help
The diagnostic examines customer segments, value propositions, pricing assumptions, monetisation pathways and commercial logic to identify where uncertainty, weak alignment or assumption-driven thinking may be creating risk.
The work helps founders and leadership teams understand whether the business model remains commercially viable, where value or pricing gaps may exist and what requires attention before investment, pricing or scaling decisions become harder to reverse later.
What you recieve
• review of business model structure and value logic
• assessment of customer alignment, pricing and revenue assumptions
• identification of commercial risks, gaps and weak value capture
• evaluation of monetisation pathways and sustainability considerations
• business model and commercial improvement recommendations
What improves
Organisations leave with clearer visibility of commercial risks, stronger understanding of value creation and pricing alignment and better-informed decisions around monetisation, investment and growth priorities.
The result is a more commercially credible and resilient business foundation — with reduced uncertainty, stronger investor confidence and greater clarity around long-term viability.
Go-to-Market Diagnosis
Build traction with focus – not guesswork..
Issues
Many early-stage teams struggle to turn promising products into real market traction because their go-to-market approach remains unclear, fragmented or based too heavily on assumptions. Without clarity around who to target, how customers make decisions or what builds trust early on, even strong products can struggle to gain visibility, engagement or adoption
As pressure to grow increases, teams often expand activity before foundations are fully validated. Messaging becomes diluted, channels become misaligned and early commercial efforts generate limited learning or momentum.
Aim
This diagnostic helps founders and leadership teams assess whether their go-to-market foundations are realistic, focused and aligned with how customers actually discover, evaluate and adopt products in real-world environments.
Why it matters
Early traction is rarely about scale — it is about clarity. Many organisations underestimate the complexity of reaching the right customers, communicating value effectively and building trust early enough to support adoption.
As assumptions replace evidence, teams can begin investing in channels, messaging or commercial activity that fail to reflect how people genuinely behave or make decisions. Over time, this weakens visibility, increases acquisition costs and slows the momentum needed to support sustainable growth.
Without a structured go-to-market foundation, organisations risk wasting time, resources and commercial energy while struggling to generate meaningful traction or learning.
The risks
Research from Harvard Business Review (2013), the Journal of Service Research (2007) and Forrester Research (2021) shows that unclear positioning, behavioural misalignment and weak customer understanding significantly reduce early adoption, increase acquisition friction and weaken long-term engagement.
These risks rarely emerge through one major commercial failure. More often, they build gradually through unclear targeting, inconsistent messaging, poorly aligned channels and early commercial decisions that fail to reflect how customers actually discover, evaluate or trust new solutions.
How we help
The diagnostic examines target segments, customer discovery pathways, messaging clarity, channel alignment and early traction assumptions to identify where uncertainty, weak alignment or commercial friction may be limiting progress.
The work helps founders and leadership teams understand whether go-to-market activity reflects real customer behaviour, where traction barriers may exist and what requires attention before larger commercial investment or scaling activity moves further forward.
What you recieve
• review of target segments, positioning and early traction assumptions
• assessment of messaging clarity, trust signals and channel alignment
• identification of commercial friction, weak targeting and adoption barriers
• evaluation of customer discovery and engagement pathways
• go-to-market and early traction improvement recommendations